Pembrolizumab first-line treatment of advanced gastric cancer

Pembrolizumab can be combined with trastuzumab, fluoropyrimidine-containing and platinum-containing chemotherapy regimens and is suitable for the first-line treatment of patients with locally advanced unresectable or metastaticHER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. It can also be suitable for the treatment of patients with locally advanced or metastatic esophagus or gastroesophageal junction (GEJ)(GEJ) (tumor center located 1-5 cm above the GEJ) cancer who are ineligible for surgical resection or definitive chemoradiotherapy, for use as a single agent after one or more systemic therapies in patients with tumors with squamous cell histology that are determined by FDA-approved trials to express PD-L1 (CPS ≥ 10).